Antineoplastic agent-associated interstitial lung disease in breast, ovarian, and prostate cancers: a pharmacovigilance study using the FDA adverse event reporting system - Takeaways - MDSpire

Antineoplastic agent-associated interstitial lung disease in breast, ovarian, and prostate cancers: a pharmacovigilance study using the FDA adverse event reporting system

  • By

  • Keyuan Du

  • Chenglong Duan

  • Jiaqi Zhang

  • Jianing Zhang

  • Jinsui Du

  • Yi Pan

  • Zhihao Liu

  • Chenrong Zhang

  • Yuhan Zhang

  • Yibin Zhang

  • Xuan Zhang

  • Zhongxia Sheng

  • Bin Wang

  • Yu Ren

  • Lizhe Zhu

  • June 10, 2026

  • 0 min

Share

  • 1

    Interstitial lung disease (ILD) is a serious adverse effect of anticancer therapy, particularly in breast, ovarian, and prostate cancers.

  • 2

    The study analyzed 8,146 FAERS reports and found trastuzumab deruxtecan (T-DXd) had the highest ILD reporting association among antineoplastic agents.

  • 3

    Older age and lower body weight were independently associated with increased ILD reporting in patients receiving anticancer therapy.

  • 4

    The literature review identified 85 publications with 98 case-level records, providing clinical context for the FAERS findings on ILD.

  • 5

    The findings indicate that ILD reporting associations vary across different antineoplastic agents, necessitating careful monitoring during treatment.

Original Source(s)

Antineoplastic agent-associated interstitial lung disease in breast, ovarian, and prostate cancers: a pharmacovigilance study using the FDA adverse event reporting system

  • by Keyuan Du, Chenglong Duan, Jiaqi Zhang, Jianing Zhang, Jinsui Du, Yi Pan, Zhihao Liu, Chenrong Zhang, Yuhan Zhang, Yibin Zhang, Xuan Zhang, Zhongxia Sheng, Bin Wang, Yu Ren, Lizhe Zhu

  • June 10, 2026

Related Content

Evaluating the efficacy and safety of first-line immunotherapy for metastatic triple-negative breast cancer: a systematic review and network meta-analysis of randomized controlled trials with a focus on PD-L1 expression

Comparison of the diagnostic power of serum circulating miR-21, VEGF, and CA15-3 in breast cancer

Combination of metformin and parthenolide inhibits breast cancer in mice by apoptosis induction and angiogenesis inhibition